SK9532003A3 - Crystalline forms of atorvastatin calcium - Google Patents

Crystalline forms of atorvastatin calcium Download PDF

Info

Publication number: SK9532003A3
Authority: SK; Slovakia
Prior art keywords: intensity; polymorphic form; crystalline polymorphic; calcium; atorvastatin calcium
Prior art date: 2000-12-27

Application number

SK953-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Der Schaaf Paul Adriaan Van

Fritz Blatter

Martin Szelagiewicz

Kai-Uwe Schoning

Original Assignee

Ciba Sc Holding Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-27

Filing date

2001-12-19

Publication date

2004-04-06

2001-12-19 Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag

2004-04-06 Publication of SK9532003A3 publication Critical patent/SK9532003A3/sk

Links

OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 39
229960001770 atorvastatin calcium Drugs 0.000 title claims abstract description 35
238000002360 preparation method Methods 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 25
239000000725 suspension Substances 0.000 claims description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 18
159000000007 calcium salts Chemical class 0.000 claims description 17
239000000843 powder Substances 0.000 claims description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
239000003960 organic solvent Substances 0.000 claims description 15
-1 (phenylamino) carbonyl Chemical group 0.000 claims description 10
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 9
OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 claims description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
239000000920 calcium hydroxide Substances 0.000 claims description 2
229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
238000000634 powder X-ray diffraction Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
238000002441 X-ray diffraction Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 5
229960005370 atorvastatin Drugs 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
150000003863 ammonium salts Chemical class 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
VVRPOCPLIUDBSA-CNZCJKERSA-M sodium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Na+].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 VVRPOCPLIUDBSA-CNZCJKERSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK953-2003A 2000-12-27 2001-12-19 Crystalline forms of atorvastatin calcium SK9532003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00811249		2000-12-27
PCT/EP2001/015012 WO2002051804A1 (fr)	2000-12-27	2001-12-19	Formes cristallines d'atorvastatine

Publications (1)

Publication Number	Publication Date
SK9532003A3 true SK9532003A3 (en)	2004-04-06

Family

ID=8175112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK953-2003A SK9532003A3 (en)	2000-12-27	2001-12-19	Crystalline forms of atorvastatin calcium

Country Status (23)

Country	Link
US (4)	US7538136B2 (fr)
EP (2)	EP1345896B1 (fr)
JP (2)	JP2004516311A (fr)
KR (1)	KR100790766B1 (fr)
CN (1)	CN1273449C (fr)
AT (1)	ATE420070T1 (fr)
AU (1)	AU2002224952B2 (fr)
CA (7)	CA2431068C (fr)
CZ (1)	CZ20032019A3 (fr)
DE (1)	DE60137364D1 (fr)
ES (1)	ES2319870T3 (fr)
HR (1)	HRP20030607A2 (fr)
HU (1)	HUP0302519A3 (fr)
IL (1)	IL156280A0 (fr)
IS (1)	IS6859A (fr)
MX (1)	MXPA03005879A (fr)
NO (1)	NO20032758D0 (fr)
NZ (1)	NZ527048A (fr)
PL (1)	PL365312A1 (fr)
PT (1)	PT1345896E (fr)
SK (1)	SK9532003A3 (fr)
WO (1)	WO2002051804A1 (fr)
ZA (1)	ZA200304297B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CZ20031495A3 (cs) *	2000-11-03	2004-01-14	Teva Pharmaceutical Industries Ltd.	Forma VII hemi-kalcium atorvastatinu
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) *	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
SK16002003A3 (sk)	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
RU2304139C2 (ru) *	2001-07-30	2007-08-10	Д-р Редди'с Лабораторис Лтд	Кристаллические формы vi и vii кальциевой соли аторвастатина
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
HUP0500616A3 (en) *	2001-08-16	2011-07-28	Teva Pharma	Processes for preparing calcium salt forms of statins
WO2003018547A2 (fr) *	2001-08-31	2003-03-06	Morepen Laboratories Ltd.	Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
MXPA04007939A (es) *	2002-02-15	2004-11-26	Teva Pharma	Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
MXPA04007995A (es)	2002-02-19	2004-11-26	Teva Pharma	Desolvatacion de solvatos de hemicalcio de atorvastatina.
US20060122403A1 (en) *	2002-09-03	2006-06-08	Sanjay Suri	Atorvastatin calcium form vi or hydrates thereof
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
EP1572643A2 (fr) *	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
EP1761489A1 (fr) *	2004-03-17	2007-03-14	Ranbaxy Laboratories Limited	Forme cristalline d'hemi-calcium d'atorvastatine
AU2004317570B2 (en)	2004-03-17	2011-01-06	Ranbaxy Laboratories Limited	Process for the production of atorvastatin calcium in amorphous form
US7875731B2 (en) *	2004-05-05	2011-01-25	Pfizer Inc.	Salt forms of [R-(R,R)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
JP4915919B2 (ja)	2004-06-11	2012-04-11	Ｓｂｉバイオテック株式会社	インターフェロン産生細胞の活性調節剤
AU2005263550C1 (en) *	2004-07-16	2013-01-17	Lek Pharmaceuticals D.D.	Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) *	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
CA2585836A1 (fr)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Procede de formation d'atorvastatine amorphe
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
CA2499047A1 (fr) *	2005-03-01	2006-09-01	Apotex Pharmachem Inc.	Methode de synthese d'un sel de semi-calcium d'atorvastatine
WO2006106372A1 (fr) *	2005-04-08	2006-10-12	EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság	Nouvelle forme polymorphe de sel d'hemicalcium d'atorvastatine cristallin
CA2547216A1 (fr) *	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
WO2007057755A1 (fr)	2005-11-21	2007-05-24	Warner-Lambert Company Llc	Nouvelles formes d’acide [r-(r,r)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique magnesium
CA2633268A1 (fr) *	2005-12-13	2007-06-21	Teva Pharmaceutical Industries Ltd.	Forme cristalline d'hemi-calcium d'atorvastatine et procedes de fabrication de celle-ci
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
EP1924556A2 (fr) *	2006-06-28	2008-05-28	Teva Pharmaceutical Industries Ltd	Formes cristallines d'atorvastatine
WO2009007856A2 (fr) *	2007-07-11	2009-01-15	Actavis Group Ptc Ehf	Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
KR20120011249A (ko) *	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) *	2015-07-23	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) *	2016-07-04	2019-10-03	ゼリア新薬工業株式会社	１，５−ベンゾジアゼピン化合物カルシウム塩の製造法
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3254219B2 (ja) *	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法
US5298627A (en) *	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
KR100431038B1 (ko) *	1995-07-17	2004-05-12	워너-램버트 캄파니 엘엘씨	결정질[ｒ-(ｒ,ｒ)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CZ20021642A3 (cs)	1999-11-17	2003-05-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy atorvastatinu vápenatého
WO2001044181A1 (fr)	1999-12-17	2001-06-21	Warner Lambert Research And Development Ireland Limited	Procede pour produire de l'atorvastatine calcique cristallin
CZ20031495A3 (cs) *	2000-11-03	2004-01-14	Teva Pharmaceutical Industries Ltd.	Forma VII hemi-kalcium atorvastatinu
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) *	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
WO2002057228A1 (fr)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatine calcique
WO2002057229A1 (fr) *	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl)	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
SK16002003A3 (sk) *	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
RU2304139C2 (ru) *	2001-07-30	2007-08-10	Д-р Редди'с Лабораторис Лтд	Кристаллические формы vi и vii кальциевой соли аторвастатина

2001
- 2001-12-19 AU AU2002224952A patent/AU2002224952B2/en not_active Ceased
- 2001-12-19 SK SK953-2003A patent/SK9532003A3/sk unknown
- 2001-12-19 PL PL01365312A patent/PL365312A1/xx not_active Application Discontinuation
- 2001-12-19 PT PT01994809T patent/PT1345896E/pt unknown
- 2001-12-19 CA CA002431068A patent/CA2431068C/fr not_active Expired - Fee Related
- 2001-12-19 EP EP01994809A patent/EP1345896B1/fr not_active Expired - Lifetime
- 2001-12-19 CA CA002623599A patent/CA2623599A1/fr not_active Abandoned
- 2001-12-19 WO PCT/EP2001/015012 patent/WO2002051804A1/fr not_active Ceased
- 2001-12-19 CA CA002622727A patent/CA2622727A1/fr not_active Abandoned
- 2001-12-19 NZ NZ527048A patent/NZ527048A/xx unknown
- 2001-12-19 KR KR1020037008685A patent/KR100790766B1/ko not_active Expired - Fee Related
- 2001-12-19 CA CA002622697A patent/CA2622697A1/fr not_active Abandoned
- 2001-12-19 HR HR20030607A patent/HRP20030607A2/hr not_active Application Discontinuation
- 2001-12-19 JP JP2002552901A patent/JP2004516311A/ja not_active Withdrawn
- 2001-12-19 AT AT01994809T patent/ATE420070T1/de not_active IP Right Cessation
- 2001-12-19 US US10/130,197 patent/US7538136B2/en not_active Expired - Fee Related
- 2001-12-19 CZ CZ20032019A patent/CZ20032019A3/cs unknown
- 2001-12-19 MX MXPA03005879A patent/MXPA03005879A/es active IP Right Grant
- 2001-12-19 CA CA002622477A patent/CA2622477A1/fr not_active Abandoned
- 2001-12-19 HU HU0302519A patent/HUP0302519A3/hu unknown
- 2001-12-19 EP EP08016057A patent/EP2000461A1/fr not_active Withdrawn
- 2001-12-19 IL IL15628001A patent/IL156280A0/xx not_active IP Right Cessation
- 2001-12-19 CN CNB018215017A patent/CN1273449C/zh not_active Expired - Fee Related
- 2001-12-19 CA CA002626317A patent/CA2626317A1/fr not_active Abandoned
- 2001-12-19 CA CA002623600A patent/CA2623600A1/fr not_active Abandoned
- 2001-12-19 ES ES01994809T patent/ES2319870T3/es not_active Expired - Lifetime
- 2001-12-19 DE DE60137364T patent/DE60137364D1/de not_active Expired - Fee Related
2003
- 2003-06-02 ZA ZA200304297A patent/ZA200304297B/en unknown
- 2003-06-17 NO NO20032758A patent/NO20032758D0/no not_active Application Discontinuation
- 2003-06-24 IS IS6859A patent/IS6859A/is unknown
2004
- 2004-06-02 US US10/860,084 patent/US20040220255A1/en not_active Abandoned
2006
- 2006-05-09 US US11/431,184 patent/US20060205805A1/en not_active Abandoned
2009
- 2009-04-17 US US12/386,413 patent/US20090281162A1/en not_active Abandoned
- 2009-05-27 JP JP2009127757A patent/JP2009221216A/ja active Pending

Also Published As

Publication number	Publication date
PL365312A1 (en)	2004-12-27
CA2622477A1 (fr)	2002-07-04
KR100790766B1 (ko)	2008-01-03
IS6859A (is)	2003-06-24
AU2002224952B2 (en)	2007-04-05
US7538136B2 (en)	2009-05-26
US20060205805A1 (en)	2006-09-14
HUP0302519A2 (hu)	2003-12-29
JP2004516311A (ja)	2004-06-03
ATE420070T1 (de)	2009-01-15
DE60137364D1 (de)	2009-02-26
US20090281162A1 (en)	2009-11-12
ZA200304297B (en)	2004-08-16
NZ527048A (en)	2004-12-24
NO20032758L (no)	2003-06-17
CA2431068A1 (fr)	2002-07-04
HRP20030607A2 (en)	2005-06-30
EP1345896B1 (fr)	2009-01-07
CA2623599A1 (fr)	2002-07-04
CA2623600A1 (fr)	2002-07-04
US20030114686A1 (en)	2003-06-19
KR20030064880A (ko)	2003-08-02
CA2622727A1 (fr)	2002-07-04
IL156280A0 (en)	2004-01-04
CA2626317A1 (fr)	2002-07-04
CN1273449C (zh)	2006-09-06
ES2319870T3 (es)	2009-05-14
US20040220255A1 (en)	2004-11-04
EP2000461A1 (fr)	2008-12-10
CA2431068C (fr)	2008-06-10
CN1483022A (zh)	2004-03-17
WO2002051804A1 (fr)	2002-07-04
EP1345896A1 (fr)	2003-09-24
NO20032758D0 (no)	2003-06-17
HUP0302519A3 (en)	2008-10-28
CZ20032019A3 (cs)	2003-10-15
PT1345896E (pt)	2009-02-19
CA2622697A1 (fr)	2002-07-04
JP2009221216A (ja)	2009-10-01
MXPA03005879A (es)	2003-09-10

Legal Events

Date	Code	Title	Description
2010-10-07	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
KR100790766B1 (ko)	2008-01-03	아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2002224952A1 (en)	2003-01-23	Crystalline forms of atorvastatin
SK7212003A3 (en)	2004-03-02	Hydrolysis of [R(R,R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
SK391091A3 (en)	2000-10-09	Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
KR20120139763A (ko)	2012-12-27	랄테그라비어 염 및 이의 결정형
EP2049479A2 (fr)	2009-04-22	Polymorphes de sels de sodium et magnesium d' atorvastatine
US20040063961A1 (en)	2004-04-01	Crystalline forms of cerivastatin sodium
SK50632006A3 (sk)	2006-09-07	Spôsob prípravy hemivápenatej soli (E)-7-[4-(4-fluórfenyl)-6- izopropyl-2-[metyl(metylsulfonyl)amino]pyrimidín-5-yl](3R,5S)- 3,5-dihydroxy-6-hepténovej kyseliny
IL186221A (en)	2011-11-30	Crystalline rosuvastatin intermediate
EP1732886B1 (fr)	2010-03-03	Polymorphes d'ester de tert-butyle d'atorvastatine et leur utilisation en tant qu'intermediaires dans la preparation d'atorvastatine
CN1902194B (zh)	2011-04-20	制备非晶态(4r-顺)-6-[2-[3-苯基-4-(苯基氨基甲酰基)-2-(4-氟苯基)-5-(1-甲基乙基)-吡咯-1-基]-乙基]-2,2-二甲基-[1,3]-二噁烷-4-基-乙酸的方法